Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics is a development-stage biopharmaceutical company that is focused on developing new medicines to treat pain and neuropathy. They have a strong pipeline focused on chronic neuropathic pain and have recently announced a new long-term extension study for their Halneuron treatment. In addition, the company has licensed their anti-viral assets to PridCor Therapeutics, providing potential future milestones and royalties. While this may not have an immediate impact on the stock, it showcases the potential for future growth and development.

Bears say

Dogwood Therapeutics is a pre-revenue company focused on developing medicines for pain and neuropathy, with its pipeline mainly targeting chronic neuropathic pain and neuropathy. The upcoming topline results from the Phase 2b CINP study, expected in September, are the most important catalyst for the company in 2026 as there are currently no approved drugs for this indication, providing significant potential for market share growth in the future. However, the company has yet to generate any revenue and plans to initiate a Phase 3 pivotal study in CINP in 1H27, posing significant financial risks for investors.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Jun 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.